Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro

A. Ledererova, L. Dostalova, V. Kozlova, H. Peschelova, A. Ladungova, M. Culen, T. Loja, J. Verner, S. Pospisilova, M. Smida, V. Mancikova

. 2021 ; 9 (8) : . [pub] -

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22012320

BACKGROUND: Anti-CD19 chimeric antigen receptor T cells (CART-19) frequently induce remissions in hemato-oncological patients with recurred and/or refractory B-cell tumors. However, malignant cells sometimes escape the immunotherapeutic targeting by CD19 gene mutations, alternative splicing or lineage switch, commonly causing lack of CD19 expression on the surface of neoplastic cells. We assumed that, in addition to the known mechanisms, other means could act on CD19 to drive antigen-negative relapse. METHODS: Herein, we studied the mechanism of antigen loss in an in vivo CD19-negative recurrence model of chronic lymphocytic leukemia (CLL) to CART-19, established using NOD-scid IL2Rgnull mice and HG3 cell line. We validated our findings in vitro in immortalized B-cell lines and primary CLL cells. RESULTS: In our in vivo CLL recurrence model, up to 70% of CART-19-treated mice eventually recurred with CD19-negative disease weeks after initial positive response. We found that the lack of CD19 expression was caused by promoter DNA hypermethylation. Importantly, the expression loss was partially reversible by treatment with a demethylating agent. Moreover, this escape mechanism was common for 3 B-cell immortalized lines as well as primary CLL cells, as assessed by in vitro coculture experiments. CONCLUSIONS: Epigenetically driven antigen escape could represent a novel, yet at least partially reversible, means of CD19 loss to CART-19 in B-cell tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012320
003      
CZ-PrNML
005      
20220506131506.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jitc-2021-002352 $2 doi
035    __
$a (PubMed)34413165
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ledererova, Aneta $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro / $c A. Ledererova, L. Dostalova, V. Kozlova, H. Peschelova, A. Ladungova, M. Culen, T. Loja, J. Verner, S. Pospisilova, M. Smida, V. Mancikova
520    9_
$a BACKGROUND: Anti-CD19 chimeric antigen receptor T cells (CART-19) frequently induce remissions in hemato-oncological patients with recurred and/or refractory B-cell tumors. However, malignant cells sometimes escape the immunotherapeutic targeting by CD19 gene mutations, alternative splicing or lineage switch, commonly causing lack of CD19 expression on the surface of neoplastic cells. We assumed that, in addition to the known mechanisms, other means could act on CD19 to drive antigen-negative relapse. METHODS: Herein, we studied the mechanism of antigen loss in an in vivo CD19-negative recurrence model of chronic lymphocytic leukemia (CLL) to CART-19, established using NOD-scid IL2Rgnull mice and HG3 cell line. We validated our findings in vitro in immortalized B-cell lines and primary CLL cells. RESULTS: In our in vivo CLL recurrence model, up to 70% of CART-19-treated mice eventually recurred with CD19-negative disease weeks after initial positive response. We found that the lack of CD19 expression was caused by promoter DNA hypermethylation. Importantly, the expression loss was partially reversible by treatment with a demethylating agent. Moreover, this escape mechanism was common for 3 B-cell immortalized lines as well as primary CLL cells, as assessed by in vitro coculture experiments. CONCLUSIONS: Epigenetically driven antigen escape could represent a novel, yet at least partially reversible, means of CD19 loss to CART-19 in B-cell tumors.
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny CD19 $x imunologie $7 D018941
650    _2
$a metylace DNA $x imunologie $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a receptory antigenů T-buněk $x imunologie $7 D011948
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dostalova, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kozlova, Veronika $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Peschelova, Helena $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Ladungova, Adriana $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Culen, Martin $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Loja, Tomas $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Verner, Jan $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pospisilova, Sarka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Smida, Michal $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic vero.mancikova@gmail.com michal.smida@ceitec.muni.cz $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000273353435
700    1_
$a Mancikova, Veronika $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic vero.mancikova@gmail.com michal.smida@ceitec.muni.cz $u Department of Internal Medicine - Oncology and Hematology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000281559927
773    0_
$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 9, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34413165 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131458 $b ABA008
999    __
$a ok $b bmc $g 1789767 $s 1163521
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 8 $e - $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options